About
Standards

By Category

RecoveryLongevityCognitiveMetabolicAestheticsImmuneGrowth hormoneHormonal

Popular

BPC-157NAD+GLP-2 (T)SemaxGHK-CuThymosin Alpha 1

Stacks

GLOW (skin)KLOW (immune)BPC/TB500 (recovery)CJC/Ipamorelin (GH)

Shop

All peptidesProduct certificatesSubscribe & save

Help

FAQContact us

Policies

ShippingReturns & refundsTerms & conditionsPrivacy policy
Affiliates
Earn 15% on every referral
Share OSYRIS, earn commission. Your audience gets 10% off.
Learn more →
AboutStandards
Home/Shop/Tissue Repair & Recovery/BPC-157
BPC-157 research peptide vial — OSYRIS Health
RECOVERY

BPC-157

$59.99

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in the gastric mucosa. Structurally stable and water-soluble, it is widely studied for its potential role in cellular signaling, tissue regeneration, and inflammation models. BPC-157 is intended solely for laboratory and in vitro research purposes.

Quantity10mg
FormulaC62H98N16O22
Mol. Weight1419.5 g/mol
PuritySee COA
Free shipping on orders over $200
Download Certificate of Analysis
Research On This Compound

BPC-157 — A complete research overview

14 min read · 11 citations · Tissue repair, GI, vascular

COMPARISON

BPC-157 vs TB-500

Two paths to tissue repair

CATEGORY GUIDE

Recovery peptides

Research mechanisms compared

DEEP DIVE

TB500 — From thymus to tissue repair

Actin, wound healing, cardiac

DEEP DIVE

GHK-Cu — Copper peptide research

Collagen, copper, gene expression

Practical Guides

How to read a certificate of analysis

Peptide storage and handling

Understanding peptide purity testing

About This Compound

Product Overview

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protein found naturally in human gastric juice called Body Protection Compound. It was first isolated and characterized by researchers at the University of Zagreb in the early 1990s, and it has since become one of the most studied peptides in preclinical research.

The compound's full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of 1419.53 g/mol. Unlike many research peptides that require refrigeration immediately, BPC-157 is notable for its stability in solution — a characteristic that makes it practical for laboratory use across a range of experimental conditions.

Most of the published research on BPC-157 focuses on three broad areas: tissue repair mechanisms, gastrointestinal cytoprotection, and vascular function. The data comes primarily from rat models, cell cultures, and in vitro assays. As of now, no human clinical trials have been completed and published in peer-reviewed journals, which is an important context for interpreting the preclinical findings summarized below.

BPC-157 tissue regeneration research visualization — OSYRIS Health
Research Applications

Mechanism and Experimental Context

BPC-157 has been studied extensively in animal models of tissue injury. Multiple studies in rats have demonstrated accelerated healing of tendons, ligaments, muscles, and skin wounds following administration of the peptide. A 2010 study by Chang et al. showed that BPC-157 promoted tendon healing in a rat model of Achilles tendon transection, with treated animals showing significantly greater tendon strength and collagen organization compared to controls.1

The proposed mechanism involves upregulation of growth factor expression — specifically, BPC-157 appears to increase levels of EGF, VEGF, and FGF in injured tissues, which are proteins that drive cell proliferation, blood vessel formation, and tissue remodeling. Studies also suggest the peptide activates the FAK-paxillin signaling pathway, which plays a role in cell migration to injury sites.2

Importantly, these findings are from animal models. The translation to human biology remains an open question in the research community.

The original research interest in BPC-157 centered on its effects in gastrointestinal models. The peptide has shown protective effects against various forms of experimentally induced GI damage in rats, including ethanol-induced gastric lesions, NSAID-induced intestinal injury, and surgically created fistulas.3

A series of studies by Sikiric et al. at the University of Zagreb demonstrated that BPC-157 reduced the severity of inflammatory bowel disease models in rats, including colitis induced by trinitrobenzene sulfonic acid. The protective effect appears to involve modulation of the nitric oxide (NO) system — the peptide has been shown to interact with both the constitutive and inducible forms of nitric oxide synthase.4

The GI research is particularly notable because BPC-157 demonstrated activity when administered orally in animal studies, unlike most peptides which are degraded by digestive enzymes before absorption. This oral stability is unusual for a peptide and has been a focus of investigation.

Several studies have investigated BPC-157's effects on blood vessel formation and vascular repair. In rat models, the peptide promoted angiogenesis (new blood vessel growth) around injury sites, which is a critical component of tissue repair. A 2014 study showed BPC-157 accelerated blood vessel formation in a rat model of ischemia, improving blood flow to oxygen-deprived tissue.5

The vascular effects appear related to BPC-157's interaction with the VEGF pathway. The peptide has been shown to increase VEGF receptor expression in endothelial cells, which could explain its pro-angiogenic activity in animal models.

Research has also explored BPC-157's effects on blood pressure regulation. In rat models, the peptide appeared to modulate nitric oxide-mediated blood pressure changes, though the exact mechanism and its physiological significance remain under investigation.6

More recent preclinical studies have examined BPC-157 in neurological models. Research in rats has shown potential effects on dopaminergic and serotonergic systems. A 2019 study demonstrated that BPC-157 attenuated behavioral and neurochemical changes in a rat model of cuprizone-induced demyelination, suggesting potential effects on myelin-related pathways.7

Other studies have explored BPC-157 in rat models of traumatic brain injury, where the peptide appeared to reduce brain edema and improve functional outcomes. These findings are preliminary and the field is still working to understand the mechanisms involved.

Explore Related Compounds

Keep the Research Trail Moving

TB500 research peptide vial — OSYRIS Health

TB500

also studied in tissue repair models

$79.99
View →
BPC/TB500 Blend research peptide vial — OSYRIS Health

BPC/TB500 Blend

combines both recovery compounds

$69.99 - $129.99
View →
KPV research peptide vial — OSYRIS Health

KPV

studied in anti-inflammatory pathways

$59.99
View →
Referenced Studies

Source Literature

[1]

Chang CH, et al. "BPC 157 enhances the growth of tendon fibroblasts in vitro." Journal of Orthopaedic Research, 2011. PubMed: PMID 20839318

[2]

Hsieh MJ, et al. "Therapeutic potential of BPC-157 on tendon-to-bone healing in a rat model." Journal of Applied Physiology, 2017. PubMed: PMID 28408695

[3]

Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design, 2011. PubMed: PMID 21861804

[4]

Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." Current Neuropharmacology, 2016. PubMed: PMID 26813123

[5]

Hrelec M, et al. "Pentadecapeptide BPC 157 and vessel formation." Current Pharmaceutical Design, 2014. PubMed: PMID 24001295

[6]

Sikiric P, et al. "Pentadecapeptide BPC 157 and the cardiovascular system." Current Pharmaceutical Design, 2014. PubMed: PMID 24001296

[7]

Perovic D, et al. "BPC 157 rescues dopamine system and counteracts cuprizone-induced demyelination." Journal of Molecular Neuroscience, 2019. PubMed: PMID 30506301

Certificate of Analysis

Batch Documentation

Current published batch documentation is surfaced on-page whenever the provider exposes a public COA asset.

BPC-157 certificate of analysis

Frequently Asked Questions

Questions About BPC-157

BPC-157 is a synthetic peptide consisting of 15 amino acids. It's derived from a naturally occurring protein found in human gastric juice called Body Protection Compound. Researchers study it in animal models and cell cultures, primarily in the context of tissue repair, gastrointestinal function, and vascular biology.

BPC stands for Body Protection Compound. The "157" refers to the specific sequence fragment — it's the 15-amino-acid segment identified and studied by researchers at the University of Zagreb beginning in the early 1990s.

No. BPC-157 is not approved by the FDA for any use. It is classified as a research chemical and is sold exclusively for laboratory research purposes. No human clinical trials have been completed and published in peer-reviewed journals as of this writing.

Most BPC-157 research involves animal models (primarily rats) and in vitro cell culture experiments. Published studies have investigated its effects in models of tendon injury, gastric ulcers, inflammatory bowel disease, vascular ischemia, and brain injury. The research is preclinical — it has not been tested in controlled human trials.

The molecular formula is C₆₂H₉₈N₁₆O₂₂ with a molecular weight of 1419.53 g/mol. The amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

Store lyophilized (freeze-dried) BPC-157 in a cool, dry place away from direct light. Refrigeration at 2-8°C extends shelf life. Once reconstituted, BPC-157 should be refrigerated and used within the timeframe appropriate for your research protocol. BPC-157 is noted for relatively good stability compared to many other research peptides.

Both are studied in tissue repair contexts, but they work through different mechanisms. BPC-157 research focuses on growth factor modulation and the FAK-paxillin pathway. TB-500 (Thymosin Beta-4 fragment) is studied for its effects on actin regulation and cell migration. Some researchers study them together to investigate whether their different mechanisms produce complementary effects.

Every batch of OSYRIS BPC-157 is tested by an independent laboratory using HPLC and LC-MS analysis. Typical batch purity is ≥99%. The Certificate of Analysis for the current batch is available for download on this page.

OSYRIS BPC-157 ships as lyophilized (freeze-dried) powder in a sealed glass vial. Reconstitution with a suitable diluent is required for research use. Research supplies such as bacteriostatic water are not included.

As of this writing, no completed human clinical trials of BPC-157 have been published in peer-reviewed journals. All current evidence comes from animal models and cell culture studies. Researchers should interpret preclinical findings with appropriate caution regarding translation to human biology.

Every Batch Tested by an Independent Lab

We publish the Certificate of Analysis for every product. See our full testing process.

See Our Standards →

All products sold by OSYRIS Health are intended for laboratory research purposes only and are not for human or veterinary use. The information provided on this page describes published scientific research and does not constitute medical advice, diagnosis guidance, or a recommendation for any specific use. Always ensure compliance with local regulations.